Burosumab
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia[1][2][3].
Product Specifications
CAS Number
1610833-03-8
Product Name Alternative
KRN23; N5KG1_C10_LH; UX-023
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Field of Research
Cancer; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/burosumab.html
Purity
99.20
Solubility
H2O
Smiles
[Burosumab]
Molecular Weight
(144.08 kDa)
References & Citations
[1]Schindeler A, et al. Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children. Front Endocrinol (Lausanne) . 2020 May 28;11:338.|[2]Colangelo L, et al. Appropriate dosing of burosumab in tumor-induced osteomalacia. Osteoporos Int. 2022 Dec 1.|[3]Lira Dos Santos EJ, et al. Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia. Int J Oral Sci. 2023 Dec 6;15 (1) :53.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6212542-01 0.1 mL
MKRN1 (E3 Ubiquitin-protein Ligase Makorin-1, RING Finger Protein 61, RNF61) (MaxLight 550)
Sign In for Pricing
View Details